1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited

0.78
EUR
-0.10
(-11.93%)
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.64
2.7
2.48
2.41
2.32
3.15
3.47
3.51
4.27
5.23
5.98
5
4.15
- -
Basic EPS, GAAP
0.83
0.85
0.8
0.71
0.55
0.62
0.64
0.39
0.74
0.96
1.28
1.11
1.26
- -
Free Cash Flow per Basic Share
0.31
0.75
0.75
0.76
0.48
0.48
0.35
0.76
0.81
1.3
1.04
1.09
1.29
- -
Dividend per Share
0.32
0.33
0.33
0.32
0.32
0.32
0.32
0.32
0.6
0.32
0.42
0.54
0.47
- -
Book Value per Share
5.36
5.92
6.4
6.8
7.04
6.97
6.99
7.01
7.14
7.72
9.31
9.88
10.67
10.67
Tangible Book Value per Share
5.24
5.77
5.74
6.19
6.47
6.43
6.49
6.84
6.86
7.46
9.05
9.63
10.43
10.43
Basic Weighted Avg Shares
827
827
827
827
827
816
781
756
755
755
755
755
755
755
Sales/Revenue/Turnover
2,187
2,229
2,055
1,993
1,920
2,570
2,706
2,656
3,224
3,951
4,517
3,778
3,135
- -
Operating Margin (%)
35.39
33.64
33.55
29.27
21.26
19.23
17.61
16.17
16.79
18.29
21.6
22.3
22.89
- -
Depreciation Expense
102
148
166
195
199
202
205
208
182
186
60
69
71
- -
Net Income, GAAP
684
705
658
589
452
506
503
295
557
723
970
840
950
- -
Effective Tax Rate (%)
20.47
18.41
17.49
15.25
23.18
24.4
21.72
25.31
22.7
21.18
21.83
26.68
25.16
- -
Profit Margin (%)
31.26
31.62
32.02
29.56
23.52
19.68
18.59
11.11
17.27
18.3
21.47
22.24
30.3
- -
Working Capital
2,697
3,064
3,139
3,578
3,851
3,873
4,025
4,324
4,601
5,117
5,721
6,149
6,794
6,794
LT Debt
- -
- -
- -
- -
- -
- -
1
15
7
1
- -
8
1
1
Total Equity
4,430
4,893
5,296
5,627
5,821
5,766
5,777
5,794
5,901
6,383
7,035
7,467
8,062
8,062
Return on Invested Capital (%)
13.72
12.23
11.03
9.09
5.46
6.42
5.62
2.31
6.77
9
10.88
8.02
6.27
- -
Return on Capital (%)
15.38
14.34
12.67
10.79
7.89
8.73
8.46
4.97
9.22
11.75
14.16
11.15
11.77
- -
Return on Common Equity (%)
16.23
15.12
12.91
10.79
7.89
8.73
8.72
5.1
9.52
11.77
14.45
11.59
12.23
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
338
309
334
LT Borrowings
- -
28
- -
LT Finance Leases
8
4
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
755
755
755
Market Capitalization
- -
- -
- -

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8,599
8,953
9,304
Cash, Cash Equivalents & STI
6,490
6,961
7,566
Accounts Receivable, Net
908
916
806
Inventories
813
722
691
Total Current Liabilities
2,450
2,428
2,510
Payables & Accruals
- -
- -
- -
ST Debt
338
309
334
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.36%
6.87%
7.97%
Free Cash Flow
11.15%
14.09%
18.36%
Net Income, GAAP
8.87%
30.48%
13.08%
Sales/Revenue/Turnover
5.55%
4.98%
-17.01%
Total Cash Common Dividend
- -
17.57%
-12.96%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4,517
2024
- -
- -
3,778
2025
- -
- -
3,135

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.28
2024
- -
- -
1.11
2025
- -
- -
1.26

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.42
2024
- -
- -
0.54
2025
- -
- -
0.47

Company Description

Company Profile APIChatGPT
CEO
Zhenjiang Li
Full Time Employees
2,822
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Luan Cheng District Shijiazhuang HE China 051430
IPO Date
Dec 2, 2004
Website
shineway.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
China Shineway Pharmaceutical Group Limited (2877.HK), an investment holding company founded in 2002 and headquartered in Shijiazhuang, Hebei Province, People's Republic of China, principally engages in the research, development, manufacturing and trading of modern Chinese pharmaceutical products targeting respiratory system diseases, cardio-cerebrovascular conditions, digestive disorders, orthopedics, pediatrics, nervous system ailments and body-strengthening medications, primarily in China and Hong Kong. The company offers an extensive portfolio of dosage forms including injections such as Qing Kai Ling Injection, Shen Mai Injection, Shu Xue Ning Injection, Shuanghuanglian Injection and Guan Xin Ning Injection; soft capsules such as Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule and Huo Xiang Zheng Qi Soft Capsule; granules such as Chuanxiong Compressed Granules, Huamoyan Granule, Shu Jin Tong Luo Granule and Paracetamol Granule; traditional Chinese medicine granules; as well as tablets like Compound Licorice Tablet, pills, oral liquids and powders, with many products featured on China's National Essential Drug List, National Medical Insurance Catalogue and Low-price Medicine Catalogue; it also trades agricultural products. In recent developments, the group successfully won bids for eight key products including Qing Kai Ling Injection, Shen Mai Injection and others through the National Procurement Alliance of Proprietary Chinese Medicine's centralized procurement of TCM products; continued growth in exclusive oral products such as Huamoyan Granule and Shu Jin Tong Luo Granule amid an overall 16.4% revenue decline to RMB3.78 billion in 2024 due to high prior-year bases and procurement impacts; reported a 13.4% drop in net profit for the year while planning respiratory system production capacity expansion with a new facility expected to obtain a production license in early 2025; and sustained R&D investments alongside a dividend payout reflecting operational resilience.

Company News

Company News APIChatGPT

  • defenseworld.net

    China Shineway Pharmaceutical Group Limited (OTCMKTS:CSWYY) Stock Short Interest Rises 213.8%